Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant carboplatin and paclitaxel for locally advanced vulvar carcinoma
NL-OMON48481Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in vulvar squamous cell carcinoma (VSCC), sponsored by Netherlands Cancer Institute. Primary endpoints: Response rate, Tumor size reduction and 1 more. Started Mar 2020; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NL-OMON48481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48481.